Oramed Pharmaceuticals Strengthens Position with Russell Index Inclusion and Robust Financial Progress

Oramed Pharmaceuticals: A Strong Financial Future

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) has made significant strides in enhancing its position within the investment landscape. Recently, the company issued a letter to shareholders detailing notable achievements, including its addition to the Russell 2000 and 3000 indices, substantial repayments of its loan to Scilex Holdings, and a robust balance sheet holding approximately $270 million in total cash and assets as of March 31, 2026.

Financial Highlights

The financial outlook for Oramed is promising, with a reported appreciation in its holdings in Alpha Tau Medical Ltd. (NASDAQ: DRTS) amounting to roughly $128 million. This investment is significant for the company's portfolio, reinforcing its commitment to strategic and diversified decision-making in its investment strategies. The strong financial performance aligns with the company's aim to maintain a thriving balance sheet that benefits its shareholders.

In addition, Oramed detailed the repayment of loans from its Scilex Holding investment. Initially providing approximately $99.5 million in secured loans, the company has since recouped around $118 million, projecting an eventual recovery of approximately $161 million. This impressive return on investment underscores Oramed’s adept management and strategic foresight in the financial sector.

Strategic Portfolio Developments

Oramed’s diversified strategy has propelled it as a pioneering company not only focused on drug development but also on intricate financial engineering. The transfer of its oral drug-delivery platform and refined oral insulin program to Lifeward, a revenue-generating medical robotics firm, is a testament to this approach. Lifeward has shown promising operational resilience, reducing its quarterly cash burn and increasing sales metrics significantly.

Furthermore, Oramed has actively engaged in the diversification of its portfolio. In addition to Alpha Tau and Scilex, other investments include Nano Dimension, BioXcel Therapeutics, and several secured loans aimed at generating robust returns across varied sectors. Each investment is carefully chosen to maximize potential and complement Oramed's core competencies.

Celebrating Index Inclusion

In an announcement dated June 17, 2026, Oramed is poised to join the prestigious Russell 2000 and Russell 3000 indices, which will officially take effect at the opening of the U.S. market on June 29, 2026. This milestone is particularly anticipated to enhance Oramed’s visibility amongst investors, broadening its shareholder base and supporting the liquidity of its stocks moving forward.

The inclusion in these indices symbolizes not only a recognition of the company's growth potential but also its commitment to transparent and effective shareholder communication. Oramed’s CEO, Nadav Kidron, expressed optimism about the impact of these developments, reinforcing the company’s mission to generate long-term value for its shareholders while strategically navigating the complexities of the biomedical industry.

CEO's Closing Remarks

In closing, Kidron highlighted the transformative changes within the company, converting its initial standalone insulin program into a substantial equity interest with a revenue-generating partner. The expected economic benefits from strategic partnerships along with a strong financial foundation will enable Oramed to pursue continued growth and opportunities in the field of pharmaceuticals.

As Oramed advances with a focus on disciplined capital deployment and strategic engagement, the coming quarters are expected to yield further updates that will illustrate the company’s growth trajectory. The confidence in generating shareholder value through its diversified portfolio stands firm, signaling a positive outlook for current and prospective investors alike.

For individuals interested in pursuing opportunities with Oramed Pharmaceuticals, further information can be gathered from their official website, facilitating a deeper dive into their strategies, financial performance, and investment potential.

For additional inquiries or updates, stakeholders may reach out to the company directly through their investor relations channels.